Moody Aldrich Partners LLC Madrigal Pharmaceuticals, Inc. Transaction History

Moody Aldrich Partners LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 23, 2024	SELL	$193.33 - $291.99 $59,932 - $90,516	-310 Reduced 6.05%	4,814 $1.35 Million
Q1 2024 Apr 29, 2024	SELL	$171.37 - $283.23 $702,445 - $1.16 Million	-4,099 Reduced 44.44%	5,124 $1.37 Million
Q4 2023 Jan 25, 2024	SELL	$120.4 - $237.13 $524,462 - $1.03 Million	-4,356 Reduced 32.08%	9,223 $2.13 Million
Q3 2023 Nov 07, 2023	BUY	$146.04 - $225.78 $387,444 - $598,994	2,653 Added 24.28%	13,579 $1.98 Million
Q2 2023 Jul 28, 2023	BUY	$203.88 - $312.0 $763,734 - $1.17 Million	3,746 Added 52.17%	10,926 $2.52 Million
Q1 2023 Apr 27, 2023	BUY	$231.06 - $307.08 $1.66 Million - $2.2 Million	7,180 New	7,180 $1.74 Million
Q4 2018 Feb 12, 2019	SELL	$94.77 - $215.54 $991,957 - $2.26 Million	-10,467 Closed	0 $0
Q3 2018 Oct 31, 2018	BUY	$207.3 - $300.31 $1.12 Million - $1.62 Million	5,395 Added 106.37%	10,467 $2.24 Million
Q2 2018 Aug 13, 2018	BUY	$101.55 - $313.9 $515,061 - $1.59 Million	5,072 New	5,072 $1.42 Million

296

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.94B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Moody Aldrich Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Moody Aldrich Partners LLC with notifications on news.